Another new antibody-drug conjugate drug for breast cancer, ‘Trodelvy,’ can now be prescribed at general

According to industry sources, Gilead Science Korea’s triple-negative breast cancer (TNBC) treatment ‘Trodelvy (sacituzumab govitecan-hziy)’ has recently passed the drug committee review of Seoul Asan Medical Center.

In addition, landing procedures for the drug are also underway at tertiary hospitals such as Samsung Medical Center, Seoul National University Hospital, and Sinchon Severance Hospital.

Trodelvy passed the Health Insurance Review and Assessment Service's Cancer Disease Review Committee in November last year and is currently awaiting review by the Drug